All Stories

  1. WSV2023 - The second meeting of the world society for virology: One health - One world - One virology
  2. Desloratadine via its anti-inflammatory and antioxidative properties ameliorates TNBS-induced experimental colitis in rats
  3. Editorial: Viral emerging and re-emerging diseases: basic understanding and future intervention strategies
  4. Comparative analysis of salivary microbiota in diabetic and non-diabetic individuals of North India using metagenomics
  5. SARS-CoV-2 Infection, Inflammation, Immunonutrition, and Pathogenesis of COVID-19
  6. Neuroprotective Effect of Levetiracetam in Combination with Berberine on Scopolamine Induced-Cognitive Impairment in Mice: A Behavioral and Biochemical Approach
  7. Transforming clinical virology with AI, machine learning and deep learning: a comprehensive review and outlook
  8. Understanding HIV-associated neurocognitive and neurodegenerative disorders (neuroAIDS): enroute to achieve the 95-95-95 target and sustainable development goal for HIV/AIDS response
  9. Appraisal of skeletal maturity indicators with respect to non invasive biomarkers
  10. Tracking the COVID-19 vaccines: The global landscape
  11. Antiviral and anti‐inflammatory activity of natural compounds against Japanese encephalitis virus via inhibition of NS5 protein and regulation of key immune and inflammatory signaling pathways
  12. Antiviral and anti-inflammatory activity of novel belladonna formulation against Japanese encephalitis virus via inhibition of p65 nuclear translocation and TNF-α mediated NF-kB signaling
  13. Infectious Diseases Annual Volume 2022
  14. Fabrication and Evaluation of Basil Essential Oil-Loaded Halloysite Nanotubes in Chitosan Nanocomposite Film and Its Application in Food Packaging
  15. Pre-clinical investigation of protective effect of nutraceutical D-glucosamine on TNBS-induced colitis
  16. Tracing the origin of Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2): A systematic review and narrative synthesis
  17. Re‐emerging human monkeypox: A major public‐health debacle
  18. Trends in Molecular Aspects and Therapeutic Applications of Drug Repurposing for Infectious Diseases
  19. Introductory Chapter: High-Throughput Screening - A New Tool for Precision Medicine
  20. High-Throughput Screening for Drug Discovery toward Infectious Diseases: Options and Challenges
  21. Pneumonia
  22. Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19
  23. Chikungunya Virus - A Growing Global Public Health Threat
  24. Association between Adaptive Evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein and Geographically Distinct Virus Epidemiology During the Initial Wave of the Coronavirus Disease 2019 Pandemic
  25. Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus‐2 Omicron Variant of Concern
  26. Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective
  27. Environmental Nanomedicine
  28. Microbicidal Nanoparticles
  29. Epstein-Barr Virus - New Trends
  30. Structural and molecular perspectives of SARS-CoV-2
  31. Therapeutic approaches for SARS-CoV-2 infection
  32. Innate Immunity in Health and Disease
  33. Pathogenesis and Host Immune Response during Japanese Encephalitis Virus Infection
  34. Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations
  35. Wound Healing Activity of a Novel Formulation SKRIN via Induction of Cell Cycle Progression and Inhibition of PCNA–p21 Complex Interaction Leading to Cell Survival and Proliferation
  36. Artificial Intelligence in Mental Healthcare During COVID-19 Pandemic
  37. Artificial Intelligence-Enabled Prognosis Technologies for SARS-CoV-2/COVID-19
  38. Use of Mobile Phone Apps for Contact Tracing to Control the COVID-19 Pandemic: A Literature Review
  39. Role of metabolomics in identifying cardiac hypertrophy: an overview of the past 20 years of development and future perspective
  40. Applications of Artificial Intelligence in COVID-19
  41. Zika Virus Disease: Progress and Prospects
  42. An Ophthalmological update for air-travellers during COVID-19
  43. The relevance of digital mental healthcare during COVID-19: Need for innovations
  44. Chasing COVID-19 through SARS-CoV-2 spike glycoprotein
  45. COVID-19 in the elderly people and advances in vaccination approaches
  46. Plant-based vaccines and antibodies to combat COVID-19: current status and prospects
  47. Recombinant vaccines for COVID-19
  48. Dengue Fever in a One Health Perspective
  49. Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection
  50. Antiviral Activity of Belladonna During Japanese Encephalitis Virus Infection via Inhibition of Microglia Activation and Inflammation Leading to Neuronal Cell Survival
  51. Mental illnesses among COVID-19 patients: Possible immunological underpinnings
  52. Viral Hepatitis E and Chronicity: A Growing Public Health Concern
  53. COVID-19: benefits and risks of passive immunotherapeutics
  54. Calcarea carbonica treatment rescues lipopolysaccharide-induced inflammatory response in human mononuclear cells via downregulation of inducible cyclooxygenase pathway
  55. Dark Classics in Chemical Neuroscience: An Evidence-Based Systematic Review of Belladonna
  56. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives
  57. Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor
  58. Hepatitis B and C
  59. High sensitivity C-reactive protein level in cerebrovascular accident
  60. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)
  61. Comparative analysis of Hemagglutinin of 2013 H3N2 Influenza A virus Indicates its Evolution from 1968 H3N2 Pandemic Influenza A virus
  62. Use of Mobile Phone Apps for Contact Tracing to Control the COVID-19 Pandemic: A Literature Review
  63. Next-Generation Rapid Advanced Molecular Diagnostics of COVID-19 by CRISPR-Cas
  64. A demographic prevalence of β Thalassemia carrier and other hemoglobinopathies in adolescent of Tharu population
  65. Animal Flaviviruses
  66. COVID-19: An Ophthalmological Update
  67. Classical Coronaviruses
  68. Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)
  69. Contemporary vaccine approaches and role of next-generation vaccine adjuvants in managing viral diseases
  70. Coping with Mental Health Challenges During COVID-19
  71. Coronavirus Disease 2019 (COVID-19)
  72. Coronavirus Infection Among Children and Adolescents
  73. Correction to: Transmission Cycle of SARS-CoV and SARS-CoV-2
  74. Current Advances in Nanotechnology and Medicine
  75. Current Insight into the Novel Coronavirus Disease 2019 (COVID-19)
  76. Diagnostic Strategies for COVID-19 and other Coronaviruses
  77. Emergence and Reemergence of Severe Acute Respiratory Syndrome (SARS) Coronaviruses
  78. Futuristic Technologies for Advanced Detection, Prevention, and Control of COVID-19
  79. Global Trends in Epidemiology of Coronavirus Disease 2019 (COVID-19)
  80. Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection
  81. Laboratory Diagnosis of Novel Coronavirus Disease 2019 (COVID-19) Infection
  82. Modern Approaches in Nanomedicine for NeuroAIDS and CNS Drug Delivery
  83. Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  84. NanoBioMedicine
  85. Nanotoxicology in Medicine
  86. Negative COVID-19 Test: What Next?
  87. Nipah Virus
  88. Opportunities in Clinical Translation and Commercialization of Nanomedicine
  89. Pandemic Influenza A Virus (pH1N1)
  90. Preparing Children for Pandemics
  91. Preparing for the Perpetual Challenges of Pandemics of Coronavirus Infections with Special Focus on SARS-CoV-2
  92. Prevention and Control Strategies for SARS-CoV-2 Infection
  93. Radiological Perspective of the Novel Coronavirus Disease 2019 (COVID-19)
  94. Therapeutic Development and Drugs for the Treatment of COVID-19
  95. Transmission Cycle of SARS-CoV and SARS-CoV-2
  96. Water-Associated Infectious Diseases
  97. Malaria
  98. Current Topics in Neglected Tropical Diseases
  99. The Global Distribution and Burden of Dengue and Japanese Encephalitis Co-Infection in Acute Encephalitis Syndrome
  100. Complementary and Alternative Medicine Treatments of Water-Associated Infectious Diseases in Alliance with Conventional Medicine Treatments
  101. Conventional Treatments of Water-Associated Infectious Diseases
  102. Emerging and Re-emerging Water-Associated Infectious Diseases
  103. Epidemiology of Water-Associated Infectious Diseases
  104. Etiological Agents of Water-Associated Infectious Diseases
  105. Evolution and Interplay of Water-Associated Human Pathogens
  106. Global Strategies and Schemes for Preventing Water-Associated Infectious Diseases
  107. Hazards Associated with Contaminated Water
  108. Impact of Climate Change on Water-Associated Infectious Diseases
  109. Introduction to Water-Associated Infectious Diseases
  110. Novel Approaches for Detecting Water-Associated Pathogens
  111. Treatment of Water to Prevent Water-Associated Infectious Diseases
  112. Correlation of Cytogenetic, Molecular and Clinical Findings in Thalassemia Patients at a Tertiary Care Hospital
  113. Hydroxyapatite–collagen augments osteogenic differentiation of dental pulp stem cells
  114. Cytogenetic Analysis of Down Syndrome Patients in Eastern Uttar Pradesh.
  115. Current Perspectives in Human Papillomavirus
  116. Recent Advances in Human Papillomavirus Infection and Management
  117. Pathogen-associated acute encephalitis syndrome: therapeutics and management
  118. Zika virus disease in India - Update October 2018
  119. Introductory Chapter: Human Influenza A Virus Infection - Global Prevalence, Prevention, Therapeutics, and Challenges
  120. Influenza - Therapeutics and Challenges
  121. Global Perspective of Novel Therapeutic Strategies for the Management of NeuroAIDS
  122. Introductory Chapter: Neglected Tropical Waterborne Infectious Diseases - Strategies for Mitigation
  123. Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements
  124. Complementary and alternative medicine in alliance with conventional medicine for dengue therapeutics and prevention
  125. Reducing the Global Burden of Dengue: Steps toward Preventive Methods
  126. Mesenchymal stem cells in regenerative medicine: a new paradigm for degenerative bone diseases
  127. Current Advances in Zika Virus Transmission: Urgency for Effective Therapeutics and Prevention
  128. Complementary and alternative medicine in alliance with conventional medicine for influenza therapeutics and prevention
  129. Proof and Concepts in Rapid Diagnostic Tests and Technologies
  130. Introductory Chapter: Serum Components as Rapid Diagnostic Biomakers During Flavivirus Infection
  131. Emerging Zika virus disease: a public health emergency of global concern
  132. Advances in Molecular Retrovirology
  133. Molecular Biology and Pathogenesis of Retroviruses
  134. Zika virus outbreak: an overview of the experimental therapeutics and treatment
  135. Investigation of Neuropathogenesis in HIV-1 Clade B and C Infection Associated with IL-33 and ST2 Regulation
  136. Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDS
  137. Japanese encephalitis: a major public-health debacle
  138. Japanese Encephalitis: A Neglected Viral Disease and Its Impact on Global Health
  139. Trends in Infectious Diseases
  140. CURRENT SCENARIO OF THERAPEUTICS FOR EBOLA VIRUS DISEASE
  141. An insight into flaviviral budding: a need to know more
  142. Towards nanomedicines for neuroAIDS
  143. Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder
  144. Current Scenario of Antiviral Drugs for Japanese Encephalitis
  145. Cocaine Enhances HIV-1 Infectivity in Monocyte Derived Dendritic Cells by Suppressing microRNA-155
  146. Latency, persistence and reactivation of Japanese encephalitis virus
  147. Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study
  148. Current Perspectives in HIV Infection
  149. NeuroAIDS: Mechanisms, Causes, Prevalence, Diagnostics and Social Issues
  150. Latest trends in drugs of abuse – HIV infection and neuroAIDS
  151. Japanese Encephalitis Virus: The Complex Biology of an Emerging Pathogen
  152. Influenza A(H1N1)pdm09 virus: therapeutics and challenges
  153. A Global Perspective on HIV/AIDS
  154. Nanotherapeutics: emerging competent technology in neuroAIDS and CNS drug delivery
  155. Modulation of HIV pathogenesis and T-cell signaling by HIV-1 Nef
  156. Targeting Strategies for Human Immunodeficiency Virus: A Combinatorial Approach
  157. HIV-1 Nef: hacker of the host cell
  158. Rendezvous with Tat: Transactivator of Transcription during Human Immunodeficiency Virus Pathogenesis
  159. Japanese Encephalitis: A Persistent Threat
  160. The Intolerable Burden of Chikungunya: What’s New, What’s Needed?
  161. Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder
  162. JAPANESE ENCEPHALITIS VIRUS: AN EMERGING PATHOGEN
  163. Japanese Encephalitis: An Emerging and Spreading Arbovirosis
  164. HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: Implication for HIV-associated neurocognitive disorder (HAND)
  165. Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS
  166. Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: Implications for HIV-1–associated neurocognitive disorder
  167. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors
  168. Escalation of Japanese encephalitis in India: Evidence from 2005 viral encephalitis outbreak and appraisal of niceties
  169. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors
  170. Structural and antigenic variance between novel influenza A/H1N1/2009 and influenza A/H1N1/2008 viruses
  171. Swine flu: Influenza A/H1N1 2009: the unseen and unsaid
  172. Trend of Japanese encephalitis in North India: evidence from thirty-eight acute encephalitis cases and appraisal of niceties
  173. Advances in antiviral drug discovery and development: Part II: Advancements in antiviral drug development
  174. Controversial role of smallpox on historical positive selection at the CCR5 chemokine gene (CCR5-Δ32)
  175. Paromomycin: Uptake and resistance in Leishmania donovani
  176. Advances in antiviral drug discovery and development: Part I: Advancements in antiviral drug discovery
  177. The Latitude Wise Prevalence of the CCR5-Δ32-HIV Resistance Allele in India
  178. Japanese encephalitis: perspectives and new developments
  179. Enzymatic and Structural Characterisation of Amphinase, a Novel Cytotoxic Ribonuclease from Rana pipiens Oocytes
  180. Re-emergence of the knotty chikungunya virus: facts, fear or fiction
  181. Differential HIV-1 replication in neonatal and adult blood mononuclear cells is influenced at the level of HIV-1 gene expression
  182. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis
  183. Reply to 'Encephalitis outbreak finds Indian officials unprepared'
  184. A Heterologous Prime‐Boost Vaccination Regimen Using ORFF DNA and Recombinant ORFF Protein Confers Protective Immunity against Experimental Visceral Leishmaniasis
  185. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen
  186. ONCONASE ® and Its Therapeutic Potential
  187. Inhibition of Japanese Encephalitis Virus Infection by Diethyldithiocarbamate is Independent of its Antioxidant Potential
  188. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani
  189. Alteration in plasma glucose levels in Japanese encephalitis patients
  190. Entry into Cells and Selective Degradation of tRNAs by a Cytotoxic Member of the RNase A Family
  191. Induction of Nitric Oxide Synthase during Japanese Encephalitis Virus Infection: Evidence of Protective Role
  192. Antiviral effect of nitric oxide during Japanese encephalitis virus infection
  193. Regulation of intestinal regeneration: New insights
  194. Interferon Enhances the Activity of the Anticancer Ribonuclease, Onconase
  195. Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction
  196. Isolation of Desulfovibrio intestinalis sp. nov. from the hindgut of the lower termite Mastotermes darwiniensis
  197. Degradation of Japanese encephalitis virus by neutrophils
  198. Role of Organized Intestinal Lymphoid Aggregates in Intestinal Regeneration
  199. Inhibition of HIV-1 Production and Selective Degradation of Viral RNA by an Amphibian Ribonuclease
  200. Role of the N Terminus in RNase A Homologues: Differences in Catalytic Activity, Ribonuclease Inhibitor Interaction and Cytotoxicity
  201. A Study of the Intracellular Routing of Cytotoxic Ribonucleases
  202. Epithelial cell proliferation and biodistribution of radiolabeled urogastrone in the gastrointestinal mucosa of young and old mice
  203. Lignocellulose degradation by microorganisms from termite hills and termite guts: A survey on the present state of art
  204. Effect of systematic interleukin-3 administration on epithelial cell proliferation in mouse intestine
  205. Extent and Role of Urogastrone in the Adaptive Response of Rat Intestine to Patching of a Surgical Defect in the Ileum
  206. Ultrastructural studies of the termite (Odontotermes obesus) gut microflora and its cellulolytic properties
  207. Association of radiolabeled urogastrone binding with regenerating intestinal mucosa and epidermal growth factor/ urogastrone producing organs in rat
  208. Effect of cobalt and nickel on growth and carboxymethyl cellulase activity ofCellulomonas spp
  209. Production and localisation of carboxymethylcellulase, xylanase and ?-glucosidase fromCellulomonas andMicrococcus spp.
  210. The Effect of Intestinal Resection and Urogastrone on Intestinal Regeneration
  211. Ethanol Has Direct Inhibitory Effects on Steroidogenesis in Human Granulosa Cells: Specific Inhibition of LH Action
  212. Effect of age on intestinal regeneration in the rabbit
  213. Effect of Eflorithine on Intestinal Regeneration